Advertisement
UK markets close in 2 hours 30 minutes
  • FTSE 100

    8,330.07
    +16.40 (+0.20%)
     
  • FTSE 250

    20,382.11
    -30.97 (-0.15%)
     
  • AIM

    777.13
    +0.71 (+0.09%)
     
  • GBP/EUR

    1.1609
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2480
    -0.0030 (-0.24%)
     
  • Bitcoin GBP

    49,844.36
    -1,174.20 (-2.30%)
     
  • CMC Crypto 200

    1,319.23
    +24.56 (+1.90%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • CRUDE OIL

    77.51
    -0.87 (-1.11%)
     
  • GOLD FUTURES

    2,324.90
    +0.70 (+0.03%)
     
  • NIKKEI 225

    38,202.37
    -632.73 (-1.63%)
     
  • HANG SENG

    18,313.86
    -165.51 (-0.90%)
     
  • DAX

    18,441.76
    +11.71 (+0.06%)
     
  • CAC 40

    8,122.52
    +46.84 (+0.58%)
     

Blood Group Typing Global Market Report 2021: COVID-19 Growth And Change

Major players in the blood group typing market are Grifols, Bio-Rad Laboratories, Immucor Inc. , Ortho Clinical Diagnostics, Quotient, BAG Health Care GmbH, AXO Science, Agena Bioscience, Merck KGaA, Beckman Coulter Inc, Sucuri Inc, Rapid Labs, AXO Science, Day Medical SA, and Novacyt Group.

New York, July 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Blood Group Typing Global Market Report 2021: COVID-19 Growth And Change" - https://www.reportlinker.com/p06103719/?utm_source=GNW


The global blood group typing market is expected to grow from $2.08 billion in 2020 to $2.34 billion in 2021 at a compound annual growth rate (CAGR) of 12.37%. The growth is mainly due to the rise in blood transfusions, cross-match testing and prenatal testing, and technology advancements in blood testing reagents and instruments. The market is expected to reach $3.59 billion in 2025 at a CAGR of 11.28%.

The blood group typing market consists of sale of blood group typing products and related services by entities (organizations, sole traders and partnerships) that provide blood group type details that are derived from certain tests. Blood group typing is a method that tells the type of blood a person has and it is done so that a person can safely donate blood or receive a blood transfusion.

The main types of blood group typing are antibody screening, cross-matching tests, ABO tests, antigen typing and human leukocyte antigen (HLA) typing.The antibody screening tests are performed in a clinical laboratory or blood bank is done to detect the presence of unexpected antibodies, like alloantibodies in the serum to antigens of the non-ABO blood group system.

Cross matching tests are performed before a blood transfusion as part of blood compatibility testing.Human leukocyte antigen (HLA) typing is a kind of genetic test used to identify certain individual variations or proteins in immune system, it is often used to match patients and donors for bone marrow or cord blood transplants.

ABO tests are done to evaluate the blood type of a person out of four types, which is A, B, AB, or O.Antigen tests are immunoassays that are used to detect the presence of a specific viral antigen and are commonly used in the diagnosis of respiratory pathogens, including influenza viruses and respiratory syncytial virus.

The products that are used for blood group typing are instruments, reagents and kits and techniques that are used are serology tests, and molecular tests. The blood group typing is used in hospital-based laboratories, independent laboratories and blood banks.

North America was the largest region in the blood group typing market in 2020.Asia Pacific is expected to be the fastest growing region in the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Technological advancements such as automated technologies for blood typing gaining traction in the blood group typing market.Major companies in the market are focusing on introduction of new type of tests based on innovative techniques that offer results in low turn-around time, with improved accuracy and efficiency.

For instance, in January 2019, Grifols S.A secured clearance from the US Food and Drug Administration (FDA) for its fully-automated analyzer Erytra Eflexis. The system is designed to test pre-transfusion compatibility utilizing the DG Gel technology.

In October 2020, Calibre Scientific, provider of life science reagents, tools, instruments?and other consumables to the lab research, diagnostics, industrial and biopharmaceutical communities, acquired Lorne Laboratories for an undisclosed amount.The acquisition will support Calibre diagnostics division and expand the expertise of the company.

Lorne Laboratories is a specialty manufacturer of blood grouping reagents and diagnostic test kits.

Increasing number of blood donations and transfusions drove the blood group typing market during the historic period.Different non-profit organizations, government organizations and other agencies are emphasizing on the importance of blood donations and transfusions and spreading awareness through various campaigns.

Increase in blood donations increased the demand for blood group typing so that the donor can know what type of blood they have. For instance, according to WHO, blood donations have increased from 2013 to 2018 with 7.8 million blood donations from voluntary unpaid donors being reported from 2013 to 2018. The increase in number of blood donations and transfusions, thereby contributed to growth of the blood typing market.

The countries covered in the blood group typing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Read the full report: https://www.reportlinker.com/p06103719/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001